ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
46 announcements with these filters
Torrent Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms full adherence to SEBI listing regulations and statutory provisions.
Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.
Torrent Pharmaceuticals confirmed full utilization of ₹10,990 Crore raised via NCDs for acquiring J.B. Chemicals shares. No deviations occurred during the quarter ended March 2026.
Torrent Pharmaceuticals Limited filed its security cover certificate for outstanding NCDs totaling ₹11,156.14 Crore. The filing confirms adequate asset coverage as of March 2026.
Torrent Pharmaceuticals fixed May 29, 2026, as the record date for final dividend eligibility. Shareholders must hold stock by this date to receive the payment.
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,197 Cr (+41.8% YoY) and net profit of ₹364 Cr (-26.9% YoY) for Q4 FY26.
Torrent Pharma reported annual consolidated revenues of ₹13,980 Crore. The board recommended a ₹9 final dividend and approved a ₹5,000 Crore enabling fundraise via QIP.
Torrent Pharmaceuticals scheduled a May 22, 2026, conference call to discuss its quarterly and annual financial results. Investors can join via provided dial-in numbers.
Torrent Pharmaceuticals will hold a board meeting on May 22, 2026. Agenda includes auditing yearly results, final dividend declaration, and proposed fund raising via QIP.
Torrent Pharmaceuticals scheduled a board meeting on May 22, 2026, to approve annual results and dividends. The board will also consider raising funds through equity.
Torrent Pharmaceuticals Limited shareholders approved the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with the company in an NCLT-convened meeting on April 28, 2026. The resolution was passed by a requisite majority representing three-fourths in value. The amalgamation marks a significant strategic consolidation for Torrent Pharma.
Equity shareholders of Torrent Pharmaceuticals Limited approved the Scheme of Amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The resolution was passed with the requisite majority through remote e-voting and e-voting at the NCLT-convened meeting held on April 28, 2026.
Torrent Pharmaceuticals Limited submitted details of four listed Non-Convertible Debentures (NCDs) totalling ₹11,000 Crore issued via private placement. The company also confirmed the redemption of NCDs (ISIN INE685A07082) on December 12, 2025. This filing maintains regulatory compliance regarding debt security disclosures for the half-year ended March 31, 2026.
Torrent Pharmaceuticals Limited received a clean report from the USFDA for its Bileshwarpura (Oncology) facility. The inspection, conducted from April 6 to April 10, 2026, concluded with zero observations. This successful regulatory outcome confirms compliance with international manufacturing standards for the oncology site.
Torrent Pharmaceuticals Limited confirmed the full utilization of proceeds from its issued Commercial Papers for the quarter ending March 31, 2026. This filing adheres to SEBI Master Circular requirements regarding debt instruments.
Torrent Pharmaceuticals Ltd reported net profit of ₹635 Cr (+26.2% YoY) for Q3 FY26.